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Abstract
Background Infection is one of the main reasons for fail-
ure of orthopedic implants. Antibacterial coatings may
prevent bacterial adhesion and biofilm formation, accord-
ing to various preclinical studies. The aim of the present
study is to report the first clinical trial on an antibiotic-
loaded fast-resorbable hydrogel coating (Defensive
Antibacterial Coating, DAC) to prevent surgical site
infection, in patients undergoing internal osteosynthesis for
closed fractures.
Materials and methods In this multicenter randomized
controlled prospective study, a total of 256 patients in five
European orthopedic centers who were scheduled to
receive osteosynthesis for a closed fracture, were randomly
assigned to receive antibiotic-loaded DAC or to a control
group (without coating). Pre- and postoperative assessment
of laboratory tests, wound healing, clinical scores and
X-rays were performed at fixed time intervals.
Results Overall, 253 patients were available with a mean
follow-up of 18.1 ± 4.5 months (range 12–30). On average,
wound healing, clinical scores, laboratory tests and radio-
graphic findings did not show any significant difference
between the two groups. Six surgical site infections (4.6%)
were observed in the control group compared to none in the
treated group (P\ 0.03). No local or systemic side-effects
related to the DAC hydrogel product were observed and no
detectable interference with bone healing was noted.
Conclusions The use of a fast-resorbable antibiotic-loaded
hydrogel implant coating provides a reduced rate of post-
surgical site infections after internal osteosynthesis for
closed fractures, without any detectable adverse event or
side-effects.
Level of evidence 2.
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Introduction
The Centers for Disease Control (CDC) healthcare-asso-
ciated infection (HAI) prevalence survey estimated
157,500 surgical site infections (SSIs) associated with
inpatient surgeries in 2011 in the USA [1] (Table 1).
In spite of improved operating room, sterilization
methods, barriers, surgical technique and routine systemic
antimicrobial prophylaxis [2–5], SSIs are still considered to
be the most common and costly healthcare-associated
infection, accounting for 31% of all HAIs among hospi-
talized patients [6, 7].
After osteosynthesis for closed fractures, early SSI had a
reported incidence of 3.9% in a large multicenter trial, with
a median time to diagnosis of 30 days [8], while wound
healing problems, like those occurring in subcutaneous
osteosynthesis [9], and the presence of co-morbidities may
increase the risk of septic complications up to 10%
[10–12]. In a more recent retrospective study, the rates of
infection within 1 year from internal osteosynthesis after
closed and open fractures have been reported to be 4.2 and
14.7%, respectively [13]. Implant-related infections often
require implant removal, with high morbidity and possible
increased mortality [9] and elevated economic and social
costs [14].
In this context, antibacterial coatings of implants may
represent an attractive option to reduce post-surgical
infections [15]. A strong recommendation was delivered in
a recent international Consensus meeting on peri-prosthetic
joint infections, concerning the need for developing
effective antibacterial surfaces that prevent bacterial
adhesion and colonization of implants and proliferation
into the surrounding tissues [16]. However, only few anti-
bacterial coating technologies are currently available in
orthopedics and trauma and, for various reasons, they are
still far from large-scale application [17, 18].
Developing a new antibacterial coating appears chal-
lenging. Since bacterial colonization, from microbial
adhesion to an established mature biofilm layer, only takes
a few hours [19], any antibacterial protection should act at
the exact time of surgery and possibly only for a few hours
or days thereafter, to minimize the risk of long-term bac-
terial resistance induction. Moreover, any new technology
has to demonstrate safety and lack of interference with
bone healing and should prove to be effective as well as
sufficiently easy to manufacture and implement into the
current clinical practice. Finally, it should be available at
an affordable price, after having passed the scrutiny of the
complex regulatory pathway [20]. Biocompatible hydro-
gels have been shown to be able to deliver pharmacological
agents locally and can be designed to meet the desired
elution pattern [21]. Recently, a fast-resorbable hydrogel
coating that can be loaded intra-operatively with various
antibacterials has been developed [22]. Based on the
observation that bacterial colonization occurs within the
first hours after implant and that short-term systemic pro-
phylaxis is equally effective as long-term to prevent post-
surgical infections [23], this coating technology introduced
for the first time the concept of ‘short-term local protec-
tion’ of the implant. In fact, a short-term local delivery
system may meet the requirements needed to win the ‘run
to the surface’, while limiting possible long-term unwanted
side-effects [24]. This novel fast-resorbable hydrogel
coating (Defensive Antibacterial Coating, DAC; Nova-
genit Srl, Mezzolombardo, Italy) is composed of covalently
linked hyaluronan and poly-D,L-lactide and is designed to
undergo complete hydrolytic degradation in vivo within
48–72 h as well as being able to completely release a
variety of different antibacterials at concentrations ranging
from 2-10%. The hydrogel showed synergistic antibacte-
rial and antibiofilm activity with various antibiotics and
antibiofilm agents in vitro [25], while in vivo it has been
proven effective in a rabbit model of highly contaminated
implant both with [26] and without systemic prophylaxis,
without interfering with bone growth [27]. Following pre-
vious brief reports [28, 29], we present the clinical results
of a multicenter European trial comparing the SSI rate
between patients treated with DAC hydrogel-coated
osteosynthesis implants and patients treated with non-
coated implants.
Materials and methods
From January 2014 to June 2015, 256 patients (Fig. 1)
were included in this prospective multicenter randomized
study. The study protocol was approved by the local Eth-
ical Committees of the five participating centers. All
patients gave their informed consent to the procedure. The
study was performed within the 7th European Framework
Programme (project #277988) and funded by the European
Commission and the participating partners (clinical insti-
tutions and the following private companies: Novagenit
SRL, Mezzolombardo, Italy, acting as project leader;
AdlerOrtho SRL, Bologna, Italy; Arcos SARL, Brignoles,
France; Belgafix SPRL, Drogenbos, Belgium).
The patients, in five European orthopedic centers, were
randomly assigned through electronic software to receive
antibiotic-loaded DAC or to a control group (without
coating).
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Inclusion criteria were the presence of a fresh
(\7 days) closed fracture requiring surgical reduction and
internal fixation with either a metal plate and/or screws
or with an intramedullary nail, in patients aged[18 -
years. Exclusion criteria were pregnancy, breast-feeding
or planning to become pregnant during the study, the
presence of a previous or active infection at site of
fracture, severe malignancies with a life expectancy of
\3 months, previous diagnosis of immune depression
(including HIV) or immune suppressive treatment for
organ transplantation, known allergy to the antibiotics or
to DAC hydrogel constituents, patient not willing or not
able to present for the follow-up consultations or if the
patient did not sign the informed consent documents or
was not able to do so.
Surgical treatment and DAC preparation
After routine preoperative work-out, all patients were
treated according to the current principles of fracture
reduction and internal osteosynthesis. The choice of the
surgical approach and the type of osteosynthesis was left to
each participating surgeon.
Systemic antibiotic prophylaxis was performed with
perioperative administration of a single dose of the
antibiotic chosen at each center [30]. All patients also
received low-weight heparin for deep vein thrombosis
prophylaxis starting on the day of surgery and for
4–6 weeks postoperatively.
Allowed fixation materials included plating, screw and
intramedullary nailing systems from Stryker Inc. (New
Table 1 Criteria for defining a surgical site infection (SSI), according to the CDC criteria (cf. https://www.cdc.gov/hicpac/SSI/table1-SSI.html)
Superficial incisional SSI
Infection occurs within 30 days after the operation and infection involves only skin or subcutaneous tissue of the incision and at least one of
the following:
Purulent drainage, with or without laboratory confirmation, from the superficial incision
Organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision
At least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat and superficial incision
is deliberately opened by surgeon, unless incision is culture-negative
Diagnosis of superficial incisional SSI by the surgeon or attending physician
Do not report the following conditions as SSI
Stitch abscess (minimal inflammation and discharge confined to the points of suture penetration)
Infection of an episiotomy or newborn circumcision site
Infected burn wound
Incisional SSI that extends into the fascial and muscle layers (see deep incisional SSI)
Deep incisional SSI
Infection occurs within 30 days after the operation if no implant is left in place or within 1 year if implant is in place and the infection
appears to be related to the operation and infection involves deep soft tissues (e.g., fascial and muscle layers) of the incision and at least one
of the following:
Purulent drainage from the deep incision but not from the organ/space component of the surgical site
A deep incision spontaneously dehisces or is deliberately opened by a surgeon when the patient has at least one of the following signs or
symptoms: fever ([38 C), localized pain, or tenderness, unless site is culture-negative
An abscess or other evidence of infection involving the deep incision is found on direct examination, during reoperation, or by
histopathologic or radiologic examination
Diagnosis of a deep incisional SSI by a surgeon or attending physician
Organ/space SSI
Infection occurs within 30 days after the operation if no implant is left in place or within 1 year if implant is in place and the infection
appears to be related to the operation and infection involves any part of the anatomy (e.g., organs or spaces), other than the incision, which
was opened or manipulated during an operation and at least one of the following:
Purulent drainage from a drain that is placed through a stab wound into the organ/space
Organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space
An abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation, or by
histopathologic or radiologic examination
Diagnosis of an organ/space SSI by a surgeon or attending physician
 Report infection that involves both superficial and deep incision sites as deep incisional SSI
 Report an organ/space SSI that drains through the incision as a deep incisional SSI
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York, USA), Smith-Nephew (London, UK) and DePuy-
Synthes (Warsaw, IN, USA), respectively.
Reconstitution of the DAC hydrogel was performed
according to the manufacturer’s instructions. Briefly, the
prefilled syringe, containing 300 mg sterile DAC powder,
was filled at surgery with a solution of 5 mL sterile water
for injection and the desired antibiotic. This allowed the
antibiotic-loaded hydrogel with a DAC concentration of
6% (w/v) and an antibiotic concentration ranging from
20-50 mg/mL to be prepared in*3–5 min, depending on
the choice of the surgeon. The surgeons could choose the
antibiotic from a list of antibacterials previously tested as
being compatible with the hydrogel, including gentamicin,
vancomycin, daptomycin, meropenem, rifampicin, and
ciprofloxacin [25] (Novagenit SRL, data on file).
According to previous studies showing the ability of the
hydrogel to resist press-fit insertion [25–27], the hydrogel
was directly spread onto the implant surface prior to its
insertion into the body, a few minutes after reconstitution.
Further hydrogel was eventually applied on the synthesis
after its positioning on the bone and at the bone-synthesis
interface, in order to achieve complete coverage of the
implant surface. Similarly, the hydrogel was applied
directly on each pre-drilled screw hole and directly on the
screws, at the time of their insertion (Fig. 2). A similar
technique was used for coating intramedullary nails and
locking screws.
Assessments
All patients underwent preoperative clinical and radio-
graphic examinations and laboratory tests. Host type was
classified according to McPherson et al. [31]. Clinical
evaluations, serum laboratory tests and radiographic
examinations were also scheduled at 6 ± 4 weeks,
3 months ± 4 weeks, and at 6, 12, 18 and 24 month-
s ± 8 weeks postoperatively.
The primary outcome of the study was the reduction of
SSI at a minimum 12-month follow-up in the treated versus
the control group. SSI was defined as the presence of
Assessed for eligibility (n=271)
Excluded  (n=15)
♦ Not meeting inclusion criteria (n=12) 
♦ Declined to participate (n=2) 
♦ Other reasons (n=1) 
Analysed  (n=126)
♦ Excluded from analysis (n=0)
Lost to follow-up (n=0)
Allocated to treated (n=128)
♦ Received allocated intervention (n=126)
♦ Did not receive allocated intervention (n=2) 
(fracture treated after 7 days)
Lost to follow-up (n=0)
Allocated to controls (n=128)
♦ Received allocated intervention (n=127)
♦ Enrolled in two studies at the same time
(n=1)
Analysed  (n=127)
♦ Excluded from analysis (n=0)
Allocation
Analysis
Follow-Up
Randomized (n=256)
Fig. 1 ‘Consort flow diagram’ of enrolled patients
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positive local clinical signs of inflammation, including
pain, redness, warmth, swelling, draining wound, fistulas,
etc., according to the CDC procedure-associated module
SSI (https://www.cdc.gov/hicpac/SSI/table1-SSI.html)
(Table 1), requiring unplanned antibiotic treatment and/or
surgery, e.g., early synthesis removal or debridement, with
or without a positive cultural examination.
Secondary outcomes were the absence of adverse events
and side-effects related to the hydrogel coating, as assessed
by clinical, laboratory and radiographic examinations.
To this aim, clinical evaluation was performed using the
SF-12 score at follow-up, while serious adverse events and
any complication or side-effects were recorded whenever
necessary at follow-up. Wound healing was assessed at 7
and 14 days using the ASEPSIS score, described by Wilson
et al. [32], while delayed wound healing was defined as
incomplete healing of the wound after 4 weeks from sur-
gery, including the presence of wound dehiscence, necrosis
or serum leakage that may need further medication but did
not require any additional surgical treatment.
Laboratory tests, including erythrocyte sedimentation
rate, C-reactive protein, hemocromocytometric, and liver
and kidney function markers, were performed at follow-up
until 6 months after surgery and whenever SSI was
suspected.
Radiographic examination was performed by an inde-
pendent radiologist not aware of the DAC treatment. Bone
healing was defined as the presence of visible bridging
between two cortices, while delayed union was defined as a
lack of bone healing 6 months after trauma. A non-union
was identified when a period of 9 months had elapsed with
no healing progress for 3 months.
Sample size calculation
The primary outcome of this trial was the rate of SSI at a
minimum of 12 months postoperation, defined as reported
above.
Two hundred and fifty-six patients listed for osteosyn-
thesis of fresh fractures were recruited to the intervention
arm or to the standard care arm. Assuming an average
expected rate of SSI after osteosynthesis of 6.0% in the
control group [8, 9, 13] and an SSI rate of 0.1% in the
treated group, a sample size of 122 patients in each arm is
sufficient to detect a clinically important difference
between the two groups with 80% power and 5% level of
significance, as calculated using a two-tailed z test of
proportions [33]. This significant expected effect size is
based upon the rate of post-surgical infection previously
investigated in animal models of implant-related infection,
using the DAC device [26]. The sample size of 256 patients
takes into account an expected drop-out rate of *9%.
Statistical analysis
In order to detect a reduction in the rate of deep SSI from
6.0 to 1.0% for a two-sided 5% level of significance and
80% power, for the selected binary outcome we needed a
total of 244 participants, assuming a chi-squared test as the
definitive analysis.
Fig. 2 The ‘Defensive Antibacterial Coating’ (DAC) hydrogel
coating is spread onto a plate and a screw for osteosynthesis in an
ankle fracture
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Baseline demographic and comorbidity data were sum-
marized to check comparability between treatment arms.
To assess whether there was any evidence of systematic
imbalance introduced by the randomization procedure, we
also undertook formal statistical testing of differences in
baseline characteristics between treatment arms using
independent samples t tests and Fisher’s exact test or chi-
squared tests, with significance set at the 5% level.
Differences between the groups for other secondary
outcomes, including clinical and laboratory tests and
complications were assessed using chi-squared and Fish-
er’s exact tests as appropriate.
Results
Overall 253 patients (126 treated and 127 controls) were
available with an average follow-up of 18.1 ± 4.5 months
(range 12–30) and were considered for further analysis
(Fig. 1).
The two groups did not differ significantly regarding
age, sex and host type. In particular, approximately half of
the patients in both groups presented with one or more
relevant co-morbidities known to increase post-surgical
infection risk (Table 2).
Perioperative data (Table 3) show that the majority of
patients were treated with plate/screws and\10% in both
groups underwent nail fixation.
Cefazolin was the most used antibiotic for short-term
systemic prophylaxis in both groups, either alone or in
association with amikacin or vancomycin.
On average, 5.7 mL (range 1–10 mL) of DAC hydrogel
was needed to coat the implant. Gentamicin and van-
comycin were the most used antibiotics, at concentrations
of 4 or 2%, respectively.
Early wound healing did not show any difference
between groups, with an average ASEPSIS score at 7 and
14 days of 1.53 ± 3.94 and 1.93 ± 5.09 in the control
group and 1.51 ± 4.14 and 1.33 ± 4.32 in the treated
group, respectively. Delayed wound healing occurred in 7
(5.5%) and 5 (3.9%) in the control and treated group,
respectively.
Unplanned antibiotic treatment during hospital stay, for
reasons other than SSI (mainly urinary or respiratory tract
infections), was reported in 12 (9.4%) and 10 (8%) patients
in the control and treated groups, respectively (P = 0.8).
At 6 months, average serum laboratory tests (hemato-
logical, renal and hepatic function) did not show any sig-
nificant difference between groups (Table 4).
At an average 12-month follow-up, average SF-12
clinical score did not differ significantly between groups
(Table 5).
Delayed union was observed in 5 (3.9%) patients in the
control group, compared to 2 (1.6%) in the treated group
(P = 0.4).
No adverse events attributable to the DAC hydrogel
were reported. No detectable interaction was observed
between the hydrogel and bone healing. Six SSIs were
reported in the control group (4.7%), compared to none in
the treated group (P = 0.03). One patient in the control
group underwent early plate removal for plate intolerance,
without reported signs of infection. Detailed information
regarding septic complications, including treatment and
outcomes are provided in Table 6.
Discussion
This is the first clinical trial reporting on the efficacy and
safety of DAC coating for internal osteosynthesis.
Concerning efficacy, this study shows that the studied
antibiotic-loaded hydrogel coating is able to significantly
reduce early SSIs after osteosynthesis, at an average
18-month follow-up. This finding is in agreement with
earlier in vivo studies [26, 27] and with a recently pub-
lished multicenter clinical trial on the use of DAC coating
in total hip and knee cementless or hybrid total joint
replacement [34]. It is also the first clinical demonstration
that short-term local prophylaxis may significantly reduce
Table 2 Demographic and preoperative data of the patients included
in the study
Controls % Treated % P
Male 57 44.9 53 42.1 0.70
Female 70 55.1 73 57.9
Total 127 100.0 126 100.0
Age (years)
Mean ± SD 58.6 ± 17.6 62.5 ± 21.2 0.11
Min–max 20–95 21–99
Host type
A 70 55.1 60 47.6 0.25
B 53 41.7 61 48.4
C 4 3.1 5 4.0
Fracture site
Femur 32 25.2 47 37.3
Tibia/knee 11 8.7 16 12.7
Ankle/foot 29 22.8 32 25.4
Clavicle 11 8.7 10 7.9
Humerus 8 6.3 6 4.8
Forearm/wrist 29 22.8 14 11.1
Hand 7 5.5 1 0.8
Host type classified according to McPherson’s classification
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Table 3 Perioperative data
Controls % Treated %
Type of fixation
Plate/screws 117 92.1 115 91.3
Intramedullary nail 10 7.9 11 8.7
Systemic prophylaxis
Cefazolin 70 55.1 69 54.8
Cefazolin + amikacin 37 29.1 31 24.6
Cefazolin + vancomicin 20 15.7 26 20.6
DAC volume (mL)
Mean ± SD N/A 5.7 ± 3.0
Min–max N/A 1–10
DAC + gentamicin N/A 78 61.9
DAC + vancomycin N/A 46 36.5
DAC + vancomicin + meropenem N/A 2 1.6
Table 4 Serum laboratory
tests at 6 months post-surgery
Controls (mean ± SD) Treated (mean ± SD) P
Erythrocyte sedimentation rate (mm/h) 14.3 ± 16 17.3 ± 17 0.32
C-reactive protein (mg/L) 4.1 ± 8.3 4.2 ± 4.6 0.93
Hemoglobin (g/100 mL) 14.6 ± 1.2 14.3 ± 1.7 0.26
White blood cells (cells/mL) 7538 ± 2079 7352 ± 1452 0.57
PMN (%) 59.2 ± 8.5 59.5 ± 7.8 0.84
Creatinine (mg/dL) 0.9 ± 0.19 0.88 ± 0.17 0.54
SGOT (U/L) 21 ± 14.6 22.8 ± 15.5 0.34
SGPT (U/L) 20.4 ± 20.7 23.9 ± 15.5 0.12
GAMMA-GT (U/L) 35.9 ± 33.5 42.5 ± 55 0.24
PMN polymorphonuclear leukocytes; SGOT Serum Glutamic Oxaloacetic Transaminase; SGPT Serum
Glutamic Pyruvic Transaminase; GAMMA-GT Gamma-Glutamyl Transferase
Table 5 Postoperative data at
the latest follow-up
Controls (N = 127) % Treated (N = 126) % P
Follow-up (months)
Mean ± SD 18.1 ± 5.2 18.1 ± 3.5 1.0
Min–max 12–30 12–26
SF-12-physical score
Mean ± SD 46 ± 11.8 49.3 ± 9.7
SF-12-mental score
Mean ± SD 54.4 ± 9.5 52.4 ± 10.6
SF-12-total score
Mean ± SD 101.7 ± 15.4 100.5 ± 14.2 0.51
Complications
Surgical site infection 6 4.7 0 0.0 0.03
Delayed wound healing 7 5.5 5 3.9 0.76
Delayed union 5 3.9 2 1.6 0.44
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post-surgical septic complications in internal osteosynthe-
sis for closed fractures.
Clinical demonstration of safety is a basic requirement of
any novel coating technology [18, 35].The reportedcombined
data fromfive European centers indicate that the device under
study can be considered clinically safe, when used in combi-
nation with internal osteosynthesis, without any
detectable local side-effects both concerning wound and bone
healing, at a medium-term follow-up. Moreover, no changes
in organ-specific serummarkers or systemic unwanted effects
were recorded. This finding is in line with previous data from
in vivo and clinical studies [26, 27, 34]. The high biocom-
patibility of its basic constituents and the short time (\3 days)
needed for complete hydrogel resorption [22, 25] make the
possible occurrence of longer term side-effects unlikely.
In isolated reports, antibacterial coatings have previ-
ously been shown to be clinically effective in reducing
septic complications; however their application to
osteosynthesis is limited [18, 28].
Silver coating is among the most extensively studied
antibacterial agents. Dissolved silver ions are biochemi-
cally active agents, able to interfere with bacterial cell
membrane permeability and cellular metabolism. Silver
also contributes to the formation of reactive oxygen species
and to other mechanisms that potentially influence
prokaryotic cells [36]. There has been concern, however,
about the toxicity of silver ions [37] and to overcome this
issue, research efforts have recently focused on new silver-
coating technologies, that are reported to reduce or even
eliminate toxicity while maintaining antibacterial effects
[38, 39]. However, despite a demonstrated clinical efficacy
and safety in two comparative studies on a limited series of
patients treated with oncological endoprosthesis [40, 41],
the routine use of silver-coated implants remains limited
while, to the best of our knowledge, its application to
fracture fixation devices has never been investigated.
A different approach, consisting of the local adminis-
tration of antibiotics in order to protect an implant, his-
torically attracted much attention in orthopedics. Buchholz
et al. first popularized the incorporation of antibiotics into
polymethylmethacrylate (PMMA) bone cement for local
antibiotic prophylaxis in cemented total joint arthroplasty
[42] and, although the use of antibiotic-loaded PMMA
coating of nails is gaining increasing interest to treat
osteomyelitis, septic non-unions and contaminated frac-
tures [43], comparative clinical studies are lacking. More-
over, PMMA may not be used as a coating for plate
osteosynthesis or screws and antibiotic-loaded PMMA may
not overcome biofilm formation and has been found to be
associated with the development of antibiotic-resistant
‘small-colony variants’ [44, 45].
Other porous biodegradable materials for local antibiotic
delivery, like collagen sponges [46], cancellous bone [47],T
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calcium phosphate [48, 49] and bioceramics [50], were not
specifically designed to protect implanted biomaterials and
their use for infection prevention in trauma is currently
limited.
Biodegradable polymers and sol–gel coatings have also
been investigated to provide a controlled antibiotic release
on titanium [51, 52] or hydroxyapatite implants [53].
However, the most known clinical applications of this
approach are probably antibiotic-loaded D-poly-lactate
acid/gentamycin intramedullary coated nails that, until
now, only showed some positive results in a limited series
of patients [17].
In this setting, an antibiotic-loaded fast-resorbable
hydrogel coating may offer ease of use, versatility and
large scale applications, opening the way to an affordable
wide application of antibacterial implant protection, as
recently shown in a multicenter trial focused on infection
prevention in total hip and knee replacement [34].
This study has some limitations. First, the follow-up is
relatively short. Although the minimum 12-month moni-
toring appears adequate to detect early post-surgical septic
complications, exceeding that defined in the IDSA
Guidelines [54], and appears adequate to detect the vast
majority of SSIs after osteosynthesis [8, 9], longer follow-
up could be useful to further investigate the ability of the
tested device to eventually prevent the occurrence of
delayed and late infections. Second, the designed study
deliberately left the participating centers free to choose the
systemic antibiotic used for prophylaxis, as well as the one
added to the hydrogel locally. To our knowledge, as there
is no clear evidence showing the superiority of one
antibiotic prophylaxis over another [55], it was decided to
leave each center free to decide the prophylaxis on the
basis of their experience and the regional microbiology,
instead of imposing a fixed arbitrary regimen. Moreover,
the main activity of the DAC hydrogel is thought to be its
anti-adhesive effect, as recently reported [56], while the
presence of the antibiotic in the hydrogel is intended to
eventually kill the remaining planktonic bacteria and is
ancillary to the main activity of the device. All things
considered, the choice to leave the centers free to choose
the type of antibiotic did finally provide homogeneous and
comparable data and may actually better simulate the real-
life possible clinical scenario once the DAC device will be
available to market. Other limitations of the study concern
the exclusion of exposed fractures or other potentially
challenging clinical situations, in which an antibacterial
coating could eventually be useful. This will be the object
of further planned studies.
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